Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Novartis Ag ADR (NY: NVS )

94.14 +1.57 (+1.70%)
Streaming Delayed Price Updated: 1:48 PM EDT, Apr 19, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Novartis Ag ADR

< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
Arvinas Enters into a Transaction with Novartis, including a Global License Agreement for the Development and Commercialization of PROTAC® Androgen Receptor (AR) Protein Degrader ARV-766 for the Treatment of Prostate Cancer
From Arvinas Inc.
Via GlobeNewswire
Novartis AG (NYSE: NVS) Highlighted for Surprising Price Action
Via Investor Brand Network
Biotech’s Role in Addressing the Pancreatic Cancer Emergency
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NYSE:NVX),(NASDAQ:IBRX),(NASDAQ:ACRS),(NYSE:NUVB) EQNX::TICKER_END 
Via FinancialNewsMedia
Novartis AG (NYSE: NVS) Records 52-Week High Friday Morning
Via Investor Brand Network
Adaptimmune Hires Chief Commercial Officer in Advance of Q3 2024 PDUFA Date for Afami-cel, a Late-stage Product in the Company's Sarcoma Franchise
Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - February 27, 2024) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company redefining... 
Via Newsfile
Erasca Announces Two Clinical Trial Collaboration and Supply Agreements for Trametinib to Evaluate Naporafenib Combination in SEACRAFT-1 and SEACRAFT-2 Trials
From Erasca, Inc.
Via GlobeNewswire
BioMedNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Appoints Liat Halpert as Head of Business Development, Sales
Via Investor Brand Network
Insufficient self-sufficiency of raw materials in Japan
Via AB Newswire
Topics Supply Chain
Exposures Supply Chain
Voyager Therapeutics stock pops 30% on deal with Novartis
Voyager Therapeutics Inc. (NASDAQ: VYGR) is a biotech in the medical sector that specializes in gene therapy for neurological diseases. Its shares took 
Via MarketBeat
2 low-priced gene therapy stocks to speculate on
Gene therapy differs from gene editing, which is getting the lion's share of headlines. While gene editing is a form of gene therapy, there are basic diffe 
Via MarketBeat
Exposures Product Safety
2 gene-editing stocks reshaping hereditary disease treatments
Gene-editing companies are making headlines for the potential to reshape the future of healthcare and the treatment of hereditary diseases. The U.S. Federal 
Via MarketBeat
A Comprehensive Study Exploring Breast Cancer Treatment Market : Key Players Gilead Sciences, Astellas, Celgene
Get an extensive Breast Cancer Treatment Market analysis of the dominant vendors, their latest products and services, and the competitive landscape of the industry. 
Via SBWire
Allergy Treatment Market Know Faster Growing Segments Now: Akorn, Pfizer, Novartis, Mylan N.V
Global Allergy Treatment Market Breakdown by Application (Hospitals, Specialty Clinics, Homecare, Others) by Type (Eye Allergy, Food Allergy, Skin Allergy, Asthma, Rhinitis, Others) by Treatment... 
Via SBWire
Anti-Inflammatory Drugs Market Boosting the Growth Worldwide 2030
Get Anti-inflammatory Drugs Market analysis, key vendors & competitive scenario of the market prepared using market research tools such as Porter’s five forces and SWOT analysis. 
Via SBWire
Gene Therapy Market Research: Exploring Market Size, Business Growth, Career Prospects, Industry Trends, and Projections for 2028
Northbrook, IL 60062 -- (SBWIRE) -- 11/27/2023 -- In May 2022, Novartis AG (Switzerland) received US FDA approval for KYMRIAH (Tisagenlecleucel) for a third indication, including relapsed or refractory... 
Via SBWire
Exposures Product Safety
2 overlooked stocks that crushed earnings but traded lower
As the third quarter 2023 earnings season ends, it's worth looking back to see which stocks may have been overlooked or mispriced on their results 
Via MarketBeat
Exposures Product Safety
Global Oncology Drugs Market Size Projected to Reach $484 Billion by 2030
EQNX::TICKER_START (OTCPK:DTCFF),(CSE:DTC),(NYSE:BMY),(NYSE:NVS),(NYSE:MRK),(OTCQX:RHHBY) EQNX::TICKER_END 
Via FinancialNewsMedia
Get Ready for Next Generation of Diabetes, Weight-Management Drugs
Via Investor Brand Network
Get Ready for Next Generation of Diabetes, Weight-Management Drugs
EQNX::TICKER_START (NASDAQ:LEXX),(NYSE:JNJ),(NYSE:SNY),(NASDAQ:AMGN),(NYSE:NVS) EQNX::TICKER_END 
Via FinancialNewsMedia
Nano Pharmaceutical Market Next Big Move: Major Giants Abbott Laboratories, Bayer AG, Novartis AG, GlaxoSmithKline
According to HTF Market Intelligence, the Global Nano Pharmaceutical market is segmented by Application (Oncology, Cardiovascular/Physiology, Antiinflammatory/Immunology, Neurology, Anti-Infective,... 
Via SBWire
Weight Loss Drugs Market Size, Share, Growth, Trends, Analysis 2028
Get an extensive Weight Loss Drugs Market analysis of the dominant vendors, their latest products and services, and the competitive landscape of the industry. 
Via SBWire
Antiparasitic Drugs Market to See Major Growth by 2023-2030 : Arbor Pharmaceuticals, GlaxoSmithKline, Cipla
Get an extensive Antiparasitic Drugs Market analysis of the dominant vendors, their latest products and services, and the competitive landscape of the industry. 
Via SBWire
Cancer Immunotherapies Market Set for More Growth : American Cancer Society, WebMD, Eli Lily and Company
Get an extensive Cancer Immunotherapies Market analysis of the dominant vendors, their latest products and services, and the competitive landscape of the industry. 
Via SBWire
Elsevier Launches New Pharmapendium, Empowering Pharma Companies to Bring Novel Drugs to Market Faster and Increase Success of Regulatory Submissions
London, United Kingdom--(Newsfile Corp. - October 10, 2023) - Elsevier, a global leader in information and data analytics, has launched... 
Via Newsfile
Topics Animal Testing
Exposures Animal Testing Product Safety
Eli Lilly, McKesson, Novartis Flash Promising Chart Action
Eli Lilly, McKesson, and Novartis are catching investors' attention with promising chart patterns and revenue growth, signaling potential buying opportunities. 
Via MarketBeat
Cardiol Therapeutics 76% YTD Gain Is A Bullish Signal Ahead Of Expected Phase III Trial Announcements ($CRDL)
Via AB Newswire
Topics Death
Exposures Death Product Safety
Are Gene Therapy Stocks The Market's Next Big Winners?
Biotechs Sarepta and BioMarin are among companies advancing cutting-edge gene therapies, although those treatments can come with a $2 million or more price. 
Via MarketBeat
Topics Artificial Intelligence
Exposures Artificial Intelligence
Preventable Vaccines Market May See a Big Move : AstraZeneca, GlaxoSmithKline, Merck
Stay up-to-date with Preventable Vaccines Market research offered by AMA Research. Check how key trends and emerging drivers are shaping this industry growth. 
Via SBWire
AI 2.0 is Here: How to Invest in a Generational Opportunity
AI is sweeping the world but don't confuse apples with oranges; here's a look at the top 5 advancements in AI and who is using it. 
Via MarketBeat
Topics Artificial Intelligence Supply Chain
Exposures Artificial Intelligence Supply Chain
How Much Pain Will Lower Medicare Prices Cause for Pharma Stocks?
Pharmaceutical stocks are holding steady as Medicare price negotiations approach, but industry diversification and innovation support future growth prospects. 
Via MarketBeat
Topics Economy
Exposures Interest Rates
< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.